Lilly(Eli) & Company
NYSE: LLY
$727.20
-$19.00 (-2.5%)
Closing Price on November 18, 2024
LLY Articles
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Published:
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
Published:
A recent research note from SunTrust Robinson Humphrey highlights some outstanding stocks that are out of favor.
Published:
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
Published:
SunTrust Robinson Humphrey analysts expect the pharmaceutical industry to outperform in 2015, driven in part by a solid new product cycle and an attractive five-year growth rate.
Published:
A new research report from the technical team at RBC cites Bristol-Myers Squibb, Eli Lilly, Mylan and Perrigo as stocks that may continue to show sector leadership.
Published:
A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to outperform this year.
Published:
One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks to buy now according to Jefferies.
Published:
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Published:
Thursday's top analyst upgrades, downgrades include Apple, Barrick Gold, Corning, Groupon, Peabody Energy and SolarCity.
Published:
In a new research report, the SunTrust Robinson Humphrey team highlights the top pharmaceutical stocks to buy for 2015.
Published:
Thursday's top analyst upgrades and downgrades from 24/7 Wall St. include ARIAD Pharmaceuticals, FedEx, Genpact, Suncor Energy, Travelers and UPS.
Published:
ThinkstockStocks have enjoyed yet another wonderful year in 2014, and the bull market is now more than five and a half years old. With the S&P 500 index up almost 14% year-to-date ahead of...
Published:
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Thursday, July 31, 2014. They include Cliffs Natural Resources, Eli Lilly, Enphase Energy, Lululemon,...
Published: